NKTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nektar Therapeutics is not a good buy for a beginner, long-term investor at this time. The stock faces significant negative sentiment due to ongoing lawsuits, trial protocol violations, and poor financial performance. While some analysts have raised price targets and see potential in its lead drug, the immediate risks outweigh the potential rewards, especially given the investor's preference for long-term stability.
The stock's MACD is negatively expanding (-1.012), indicating bearish momentum. RSI is neutral at 41.933, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading near a key support level (S1: 70.205). This suggests limited immediate upside potential.
The drug has shown promise in Phase 2 trials for atopic dermatitis and alopecia areata, with potential for significant market share.
The company is facing multiple lawsuits related to trial protocol violations, which have significantly impacted investor confidence. Hedge funds are aggressively selling, with a 1229.84% increase in selling activity last quarter. Recent financial performance is poor, with revenue down 25.25% YoY and net income down 596.89% YoY.
In Q4 2025, revenue dropped by 25.25% YoY to $21.8M, net income plummeted by 596.89% YoY to -$36.1M, and EPS fell by 440.38% YoY to -1.77. While gross margin improved to 100%, the overall financial health is weak.
Analyst sentiment is mixed. While some firms like H.C. Wainwright and B. Riley have raised price targets significantly, others like Wedbush remain neutral due to concerns over trial data validity and limited near-term catalysts. The consensus reflects uncertainty rather than strong conviction.
